Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INSM |
---|---|---|
09:32 ET | 30530 | 60 |
09:34 ET | 9334 | 59.5 |
09:36 ET | 29791 | 59.415 |
09:38 ET | 11726 | 59.215 |
09:39 ET | 13516 | 58.97 |
09:41 ET | 7025 | 58.82 |
09:43 ET | 14631 | 58.94 |
09:45 ET | 7506 | 58.775 |
09:48 ET | 13940 | 59 |
09:50 ET | 7646 | 58.81 |
09:52 ET | 9379 | 59.1322 |
09:54 ET | 9099 | 59.16 |
09:56 ET | 7060 | 59.065 |
09:57 ET | 12898 | 58.665 |
09:59 ET | 7088 | 58.74 |
10:01 ET | 3484 | 58.7 |
10:03 ET | 6338 | 58.64 |
10:06 ET | 14423 | 58.46 |
10:08 ET | 12813 | 58.495 |
10:10 ET | 6500 | 58.4 |
10:12 ET | 16487 | 58.15 |
10:14 ET | 10620 | 58.12 |
10:15 ET | 9194 | 58.01 |
10:17 ET | 10838 | 58.155 |
10:19 ET | 11161 | 58.65 |
10:21 ET | 7051 | 58.665 |
10:24 ET | 10921 | 58.535 |
10:26 ET | 6873 | 58.61 |
10:28 ET | 3560 | 58.56 |
10:30 ET | 30762 | 58.98 |
10:32 ET | 172530 | 59.8738 |
10:33 ET | 18186 | 60 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Insmed Inc | 9.3B | -11.5x | --- |
Ascendis Pharma A/S | 8.0B | -13.8x | --- |
Legend Biotech Corp | 8.3B | -16.7x | --- |
Intra-Cellular Therapies Inc | 7.2B | -59.0x | --- |
Blueprint Medicines Corp | 6.5B | -21.3x | --- |
Vaxcyte Inc | 7.7B | -17.1x | --- |
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.3B |
---|---|
Revenue (TTM) | $315.5M |
Shares Outstanding | 163.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-5.23 |
Book Value | $-2.24 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 29.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -224.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.